Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | RORC | P51449 | 6/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 4/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149943 | 1.00 | USP30 (0.45) | USP30GPR119RORCPDK2CYP11B2 | |
| SCHEMBL3766313 | 0.93 | GPR119 (0.48) | USP30GPR119RORCPDK2PKLR | |
| SCHEMBL14660533 | 0.90 | RORC (0.45) | USP30GPR119RORCPDK2CYP11B2 | |
| SCHEMBL1329957 | 0.90 | GPR119 (0.44) | USP30GPR119RORCPDK2 | |
| SCHEMBL2429042 | 0.88 | USP30 (0.44) | USP30RORCPDK2CYP11B2SCD5 | |
| SCHEMBL2424588 | 0.84 | GPR119 (0.43) | USP30GPR119RORCPDK2CYP11B2 | |
| SCHEMBL30149944 | 0.84 | GPR119 (0.43) | USP30GPR119RORCPDK2CYP11B2 | |
| SCHEMBL1513306 | 0.83 | PDK2 (0.49) | GPR119RORCPDK2HDAC1HDAC8 | |
| SCHEMBL1812162 | 0.81 | CYP11B2 (0.46) | USP30GPR119RORCPDK2CYP11B2 | |
| SCHEMBL31513747 | 0.81 | RORC (0.39) | USP30GPR119RORCPDK2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400505-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2024-12-05 | — | — | US | disclosed |
| US-12091384-B2 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2024-09-17 | — | — | US | disclosed |
| EP-3625213-B1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE FUMARATE, A PROCESS FOR ITS PREPARATION AND USES THEREOF | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2023-03-08 | — | — | EP | disclosed |
| CN-110621659-B | (+) -3- (2,3-difluorophenyl) -3-methoxy pyrrolidine or pharmaceutically acceptable salt thereof, preparation method and application thereof | 综合研究实验室瑞典股份公司 | 2023-02-28 | — | — | CN | disclosed |
| US-20210317081-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2021-10-14 | — | — | US | disclosed |
| US-20210317081-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2021-10-14 | — | — | US | disclosed |
| US-11078158-B2 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2021-08-03 | — | — | US | disclosed |
| US-11078158-B2 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2021-08-03 | — | — | US | disclosed |
| US-20200024231-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-01-23 | — | — | US | disclosed |
| US-20200024231-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2020-01-23 | — | — | US | disclosed |
| US-8188301-B2 | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-05-29 | — | — | US | disclosed |
| US-20110257241-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-10-20 | — | — | US | disclosed |
| US-20110257242-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-10-20 | — | — | US | disclosed |
| EP-2367787-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | disclosed |
| EP-2367788-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2011-09-28 | — | — | EP | disclosed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | disclosed |
| WO-2010058019-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010058018-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-05-27 | — | — | WO | disclosed |
| EP-2155671-A2 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148801-A2 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078158-B2 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof | FIP1L1, SF3B2, QDPR | USP30 3609/4885GPR119 2317/4885RORC 1721/4885 |
| US-12091384-B2 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof | CYP2C9, QDPR, CYP3A43 | USP30 4114/4885GPR119 1728/4885RORC 1569/4885 |
| US-20200024231-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | FIP1L1, SF3B2, QDPR | USP30 3609/4885GPR119 2317/4885RORC 1721/4885 |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, DBH, SLC6A2 | USP30 3497/4885GPR119 753/4885RORC 3559/4885 |
| US-20240400505-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | FIP1L1, CYP2C9, QDPR | USP30 4002/4885GPR119 2064/4885RORC 1723/4885 |
| US-20110257242-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, COMT, SLC6A3 | USP30 3591/4885GPR119 410/4885RORC 2642/4885 |
| US-20210317081-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | CYP2C9, QDPR, CYP3A43 | USP30 4114/4885GPR119 1728/4885RORC 1569/4885 |
| US-20110257241-A1 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, COMT, SLC6A3 | USP30 3511/4885GPR119 342/4885RORC 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.